Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kiromic Biopharma Inc (NQ: KRBP )

0.1911 -0.0179 (-8.56%)
Streaming Delayed Price Updated: 1:44 PM EST, Feb 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Kiromic Biopharma Inc

< Previous 1 2 Next >
NASDAQ:KRBP Long Term Investor Alert: Investigation over Possible Wrongdoing at Kiromic BioPharma, Inc.
San Diego, CA -- (SBWIRE) -- 11/09/2022 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors of Kiromic BioPharma, Inc.. 
Via SBWire
Kiromic BioPharma Arranges Up to $10 Million Financing
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Announces FDA Feedback from Type B Pre-IND Meeting Confirms Deltacel Development Strategy
From Kiromic BioPharma, Inc.
Via Business Wire
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Kiromic BioPharma, Inc. (KRBP) Investors of Class Action and to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Coinbase, Carvana, Kiromic, and LifeStance and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via Globe NewsWire
KRBP DEADLINE ALERT: ROSEN, A TOP RANKED FIRM, Encourages Kiromic BioPharma, Inc. Investors With Losses to Secure Counsel Before Important October 4 Deadline in Securities Class Action - KRBP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
Exposures Financial Legal Securities Market
KIROMIC DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Kiromic BioPharma, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Kiromic BioPharma, Inc. (NASDAQ:KRBP) Investor Notice: Deadline in Lawsuit on October 4, 2022
San Diego, CA -- (SBWIRE) -- 09/29/2022 -- A deadline is coming up on October 4, 2022 in the lawsuit filed for certain investors of Kiromic BioPharma, Inc. (NASDAQ:KRBP). 
Via SBWire
ROSEN, A TOP RANKED LAW FIRM, Encourages Kiromic BioPharma, Inc. Investors to Secure Counsel Before Important October 4 Deadline in Securities Class Action - KRBP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
Exposures Financial Legal Securities Market
NATIONALLY RANKED ROSEN LAW FIRM Encourages Kiromic BioPharma, Inc. Investors to Secure Counsel Before Important October 4 Deadline in Securities Class Action - KRBP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
Exposures Financial Legal Securities Market
Kiromic BioPharma, Inc. Shareholder Reminder: Kessler Topaz Meltzer & Check, LLP Reminds KRBP Investors of Securities Fraud Class Action Lawsuit Filed On Their Behalf
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
TOP RANKED ROSEN LAW FIRM Encourages Kiromic BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - KRBP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
Exposures Financial Legal Securities Market
ROSEN, LEADING INVESTOR COUNSEL, Encourages Kiromic BioPharma, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - KRBP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
Exposures Financial Legal Securities Market
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Kiromic BioPharma, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - KRBP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
Exposures Financial Legal Securities Market
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Kiromic BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - KRBP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
Exposures Financial Legal Securities Market
Kiromic Biopharma, Inc. Shareholder News: Robbins LLP is Investigating Kiromic Biopharma, Inc. (KRBP) on Behalf of Shareholders
From Robbins LLP
Via Business Wire
NASDAQ:KRBP Shareholder Notice: Lawsuit Alleges Securities Laws Violations by Kiromic BioPharma, Inc.
San Diego, CA -- (SBWIRE) -- 08/19/2022 -- An investor, who purchased NASDAQ:KRBP shares, filed a lawsuit against Kiromic BioPharma, Inc over alleged violations of Federal Securities Laws by Kiromic... 
Via SBWire
Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed against Kiromic BioPharma, Inc. (KRBP) and Encourages Investors with Significant Losses to Contact the Firm
From Kessler Topaz Meltzer & Check, LLP
Via Business Wire
Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Kiromic BioPharma, Inc. (KRBP) Investors of Class Action and to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Kiromic BioPharma, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - KRBP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
Exposures Financial Legal Securities Market
ROSEN, GLOBALLY RECOGNIZED INVESTOR COUNSEL, Encourages Kiromic BioPharma, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - KRBP
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Topics Initial Public Offering Lawsuit
Exposures Financial Legal Securities Market
Kiromic Biopharma, Inc. Shareholder Update: Robbins LLP Reminds Investors of Class Action Against Kiromic Biopharma, Inc. (KRBP)
From Robbins LLP
Via Business Wire
EQUITY ALERT: Rosen Law Firm Encourages Kiromic BioPharma, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – KRBP
From The Rosen Law Firm, P.A.
Via Business Wire
Shareholder Alert: Robbins LLP Informs Investors of Class Action Against Kiromic Biopharma, Inc. (KRBP)
From Robbins LLP
Via Business Wire
KIROMIC ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Kiromic BioPharma, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Kiromic BioPharma, Inc. with Losses of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
Kiromic BioPharma Appoints Leonardo Mirandola, Ph.D. as Chief Scientific Officer
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Achieves Milestone with Timely Completion of Expanded cGMP Manufacturing Facility to Support Cell Therapy Oncology Pipeline
From Kiromic BioPharma, Inc.
Via Business Wire
Kiromic BioPharma Pipeline to Prioritize a New Gamma Delta T-cell Product Candidate
From Kiromic BioPharma, Inc.
Via Business Wire
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.